Masimo Corp banner

Masimo Corp
NASDAQ:MASI

Watchlist Manager
Masimo Corp Logo
Masimo Corp
NASDAQ:MASI
Watchlist
Price: 178.63 USD -0.04% Market Closed
Market Cap: $9.4B

EV/S

6.3
Current
39%
More Expensive
vs 3-y average of 4.6

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
6.3
=
Enterprise Value
$9.7B
/
Revenue
$1.5B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
6.3
=
Enterprise Value
$9.7B
/
Revenue
$1.5B

Valuation Scenarios

Masimo Corp is trading above its 3-year average

If EV/S returns to its 3-Year Average (4.6), the stock would be worth $128.52 (28% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-67%
Maximum Upside
No Upside Scenarios
Average Downside
43%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 6.3 $178.63
0%
3-Year Average 4.6 $128.52
-28%
5-Year Average 4.8 $135.6
-24%
Industry Average 2.1 $58.39
-67%
Country Average 3 $85.81
-52%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
$9.7B
/
Jan 2026
$1.5B
=
6.3
Current
$9.7B
/
Dec 2026
$1.7B
=
5.8
Forward
$9.7B
/
Dec 2027
$1.8B
=
5.4
Forward
$9.7B
/
Dec 2028
$1.9B
=
5.1
Forward
$9.7B
/
Dec 2029
$2B
=
4.8
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close
Market Cap EV/S P/E
US
Masimo Corp
NASDAQ:MASI
9.3B USD 6.3 -61.4
US
Intuitive Surgical Inc
NASDAQ:ISRG
171.2B USD 16.4 60
US
Abbott Laboratories
NYSE:ABT
158.3B USD 3.5 25.2
US
Stryker Corp
NYSE:SYK
125.3B USD 5.4 38.6
IE
Medtronic PLC
NYSE:MDT
106.9B USD 3.6 23.2
US
Boston Scientific Corp
NYSE:BSX
92B USD 5 31.8
DE
Siemens Healthineers AG
XETRA:SHL
40B EUR 2 18.9
US
Edwards Lifesciences Corp
NYSE:EW
48.9B USD 7.4 45.5
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.1B USD 10.6 42.6
US
Becton Dickinson and Co
NYSE:BDX
43.3B USD 2.7 24.7
US
Resmed Inc
NYSE:RMD
32B USD 5.7 21.6

Market Distribution

Higher than 75% of companies in the United States of America
Percentile
75th
Based on 11 256 companies
75th percentile
6.3
Low
0 — 1.6
Typical Range
1.6 — 5.3
High
5.3 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.6
Median 3
70th Percentile 5.3
Max 4 613 320.1

Masimo Corp
Glance View

Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively. In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.

MASI Intrinsic Value
123.84 USD
Overvaluation 31%
Intrinsic Value
Price $178.63
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett